top of page
swash-bg-blue.png

A Lung Health Company

banner-renovion-contact-family-in-park.jpg
At Renovion, we treat people with diseases characterized by mucus, inflammation, and an increased risk of bacterial infection.
renovion-swash-blue-1-150ppi.png
Leadership
renovion-headshots-hal.png

Hal Craig

Chemistry, Manufacturing, Controls Strategy, and Operations

renovion-headshots-zamora.png

Marty Zamora, MD

Chief Medical Officer

renovion-headshots-carolyn.png

Carolyn Durham, PhD

Chief Scientific Officer

renovion-headshots-cathy.png

Cathy Alsop, MS

Clinical Trial Manager

Our Story

In the last five years, mucus has become a main focus in treating chronic inflammatory airways diseases, such as non-cystic fibrosis bronchiectasis (NCFBE). It not only directly contributes to the vicious cycle of excess mucus secretion, chronic inflammation, and tenacious infections, but also a significant contributor to progressive declines in quality of life.

 

ARINA-1 has been shown to not only restore mucociliary clearance and ciliary function and expression, but also downregulate inflammation. It also has a potent secondary antibacterial mechanism that helps protect the lungs from bacterial growth. ARINA-1 restores lung health by clearing mucus, downregulating inflammation, and inhibiting bacterial growth. Individuals who have used ARINA·1 report significantly improved quality of life and decreased mucus burden.

Renovion is targeting three main indications: prevention of bronchiolitis obliterans (BOS) progression in bilateral lung transplant, non-CF bronchiectasis (NCFBE), and non-tuberculous mycobacteria-lung disease (NTM-LD). ARINA-1 is a next generation mucolytic that can
improve people’s lives and change the course of their disease.

Target Indications

In our target diseases, thick mucus often accumulates in the lungs and cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing.

renovion-swash-blue-1rgb-72ppi.png

Pipeline

Pre-Clinical
Phase 1
Phase 2
Phase 3
Patient Enrollment

TBD

* = Investigator-sponsored

renovion-swash-blue-1rgb-72ppi.png

Partner

copd-foundation-450-1200x720.jpg

As sponsors of the Bronchiectasis Registry, the COPD Foundation has helped Renovion design a trial to meet the needs of this patient population with no FDA-approved treatments today.

renovion-swash-blue-1rgb-72ppi.png
bottom of page